Michael Walsh

IVW 2026 | 22nd International Vasculitis Workshop Join the 22nd International Vasculitis Workshop, a leading event dedicated to advancing research, treatment, and understanding of vasculitis. Connect with global experts, researchers, and practitioner...

Amazing #ANZSN meeting in Perth. First class science (🤯 young investigators), ideas for future meetings, and caught up with friends and colleagues. Melbourne for the vasculitis-melbourne2026.com next!

Sorry I could not attend #nephjc but happy you discussed #ACHIEVE
More data coming. Was able to present some of the results by country at the ANZSN meeting in Perth at the same time as NephJC
See @dialysisbloke.bsky.social account for pics!

Safety and efficacy of steroidal mineralocorticoid receptor antagonists in patients with kidney failure requiring dialysis: a systematic review and meta-analysis of randomised controlled trials Mineralocorticoid receptor antagonists can prevent cardiovascular events in patients with heart failure and non-severe chronic kidney disease, but the…

Following #ACHIEVE our meta-analysis of RCTs of MRAs for pts receiving dialysis in @thelancet.com. Thanks to @lonniepyne.bsky.social for leading. No signal for benefit among low-risk of bias RCTs and a good demo of why we continue to need large simple trials.
www.sciencedirect.com/science/arti...

Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial Patients undergoing maintenance dialysis for kidney failure are at substantial risk of cardiovascular morbidity and mortality. We aimed to establish i…

Proud to have worked with colleagues and friends around the world on #ACHIEVE. We're disappointed spiro didn't prevent CV death/heart failure hospitalizations, but we've shown it's possible to do publicly funded large RCTs of repurposed meds in ESKD. More to do!
www.sciencedirect.com/science/arti...

Fellowships - International Society of Nephrology %

Int Society of Nephrology Glomerular Disease fellowships! Our program is not on the small ISN list but can host ISN fellows. We offer glomerular disease clinics, vasculitis clinics, genetics clinics, onconeph clinics and research opportunities. DM if interested!
www.theisn.org/in-action/gr...

The International Vasculitis Workshop is coming up! One of my favorite meetings for it's sense of community, and possibilities of forming meaningful collaborations (PEXIVAS was hatched in one of them). Call for early career scientists is here
mailchi.mp/icmsaust/ivw...

YouTube video by MARKUS at HOMe 62nd ERA Congress - Profs. L. Pyne, F. Fakhouri, M. Walsh, H. Mann, N. Staplin, V. Stel & J. Barratt

MARKUS at HOMe recap of #ERA2025 late breakers youtu.be/HbUEh8oLB2M?...
@lpyne.bsky.social

The Aldosterone Blockade for Health Improvement Evaluation in End-Stage Renal Disease (ACHIEVE) Trial: Rationale and Clinical Research Protocol - Michael Walsh, David Collister, Martin Gallagher, Patr... Background: The mineralocorticoid aldosterone may contribute to the risk of cardiovascular morbidity and mortality in patients receiving maintenance dialysis. W...

It's been a long journey but today we can share the methods and rationale for the #ACHIEVEtrial (Spiro vs placebo for patients with kidney failure receiving maintenance dialysis) and tomorrow we share the results at #era25
journals.sagepub.com/doi/10.1177/...